NCT07412197 — Radboud University Medical Center cancer vaccine trial
Preventive Dendritic Cell Vaccination for Lynch Syndrome
Registry record
| Registry ID | NCT07412197 ↗ |
|---|---|
| Lead sponsor | Radboud University Medical Center |
| Collaborators | Dutch Cancer Society |
| Phase | Phase 1/2 |
| Status | Not Yet Recruiting |
| Indication | Lynch Syndrome |
| Enrollment | 16 participants (target) |
| Start date | 2026-10 |
| Primary completion | 2029-12 (est.) |
| Last registry update | 19 Aug 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07412197), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07412197?
NCT07412197 (Preventive Dendritic Cell Vaccination for Lynch Syndrome) is registered on ClinicalTrials.gov as Phase 1/2, sponsored by Radboud University Medical Center.
Is NCT07412197 recruiting?
As of the 2026-08-19 registry update, NCT07412197 is listed as "Not Yet Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07412197?
The lead sponsor is Radboud University Medical Center. Collaborators: Dutch Cancer Society.
What condition does NCT07412197 study?
The registered condition is Lynch Syndrome. Primary completion is listed as 2029-12 (estimated).
Are results available for NCT07412197?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07412197.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.